GleamWall
中文EN

EVFM Evofem Biosciences, Inc.

Pharmaceutical Preparations · OTC · SEC CIK 1618835 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-0.0%
TTM net income YoY-133.9%
TTM EPS YoY-150.0%
Revenue 3-yr CAGR9.3%
Net income 3-yr CAGR—

Margins

Gross margin75.9%
Operating margin-16.8%
Net margin-71.7%
FCF margin—
EBITDA margin-16.7%

Returns

ROE—
ROA-120.6%
ROIC (approx.)—
Asset turnover1.68x

Leverage & solvency

Liabilities / assets1,184.7%
Debt / equity—
Current ratio0.07x
Interest coverage-1.18x

Cash quality & payout

Operating cash flow / net income0.05x
Accruals ratio-115.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$4.63M$2.63M$899,000$9.56M$4.95M$4.83M$845,000$7.10M
Cost of revenue$750,000$511,000$410,000$2.59M$905,000$755,000$365,000$1.51M
Gross profit$3.88M$2.12M$489,000$6.97M$4.05M$4.07M$480,000$5.59M
R&D expense———————$649,000
SG&A expense$1.25M$1.83M$2.37M$1.10M$2.09M$1.84M$2.37M$3.42M
Operating income$740,000-$2.49M-$4.57M$3.35M$951,000-$1.25M$327,000-$1.00M
Interest expense$682,000$626,000$614,000$606,000$599,000$588,000$577,000$570,000
Pretax income$1.00M-$11.04M-$5.47M$2.79M-$1.57M-$1.78M$956,000-$3.04M
Income tax$0$0-$1,000-$1,000-$4,000$7,000——
Net income$1.00M-$11.04M-$5.46M$2.79M-$1.57M-$1.78M$956,000-$3.04M
EBITDA$743,000-$2.48M-$4.57M$3.35M$955,000-$1.25M$333,000-$998,000
EPS (basic)0.01-0.08-0.04—-0.01-0.010.01—
EPS (diluted)0.00-0.08-0.04—-0.01-0.010.00—
Weighted avg. shares (diluted)6.81B137.34M133.25M—124.39M120.49M6.16B—
Balance sheet
Cash & equivalents$317,000$285,000$1.49M$578,000$840,000$748,000$1.11M$741,000
Receivables$3.66M$2.50M$560,000$12.48M$4.43M$4.93M$1.15M$9.83M
Inventory$1.23M$2.15M$1.89M$1.13M$1.68M$1.91M$2.26M$1.58M
Current assets$5.96M$6.08M$6.06M$15.28M$7.92M$8.97M$5.87M$13.61M
PP&E, net$409,000$412,000$416,000$418,000$420,000$424,000$429,000$458,000
Intangibles$762,000$869,000$778,000$4.35M$5.24M$4.74M$6.49M$9.60M
Total assets$7.26M$7.52M$7.44M$20.27M$13.81M$14.38M$12.88M$23.79M
Current liabilities$84.78M$88.61M$78.75M$84.82M$78.19M$73.89M$70.85M$80.45M
Short-term debt$1.01M$362,000—$147,000$291,000$383,000—$135,000
Total liabilities$86.02M$90.01M$80.15M$89.71M$83.98M$79.21M$77.68M$90.26M
Shareholders' equity-$83.93M-$87.52M-$77.63M-$74.34M-$75.07M-$69.62M-$69.59M-$71.26M
Shares outstanding132.53M132.53M132.53M126.69M123.96M118.66M113.36M113.36M
Cash flow statement
Operating cash flow$214,000-$3.14M$2.30M$31,000$336,000-$2.92M$560,000-$2.41M
Capital expenditure—$0$2,000$3,000$0——$0
Free cash flow—-$3.14M$2.30M$28,000$336,000——-$2.41M
Investing cash flow$0$0-$2,000-$3,000$0-$2,000-$57,000-$46,000
Financing cash flow-$182,000$1.05M-$498,000-$290,000-$244,000$2.56M-$135,000$2.47M
Depreciation & amortization$3,000$4,000$4,000$5,000$4,000$4,000$6,000$5,000
Stock-based compensation$0$0$15,000$42,000$23,000$31,000$70,000$188,000

Free plan shows the latest 8 periods; Pro shows all 51 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.